BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 856 filers reported holding BAXTER INTL INC in Q2 2024. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,571,280 | +337.7% | 46,974 | +459.2% | 0.06% | +364.3% |
| Q1 2024 | $359,016 | -81.6% | 8,400 | -83.3% | 0.01% | -67.4% |
| Q4 2023 | $1,946,647 | -60.5% | 50,353 | -61.4% | 0.04% | -60.6% |
| Q3 2023 | $4,924,995 | +4.8% | 130,498 | +26.5% | 0.11% | -1.8% |
| Q2 2023 | $4,698,603 | -47.3% | 103,130 | -53.1% | 0.11% | -51.1% |
| Q1 2023 | $8,912,492 | -39.5% | 219,736 | -24.0% | 0.23% | -46.1% |
| Q4 2022 | $14,735,427 | – | 289,100 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 16,850,000 | $1,473,870,000 | 17.51% |
| SECTOR GAMMA AS | 472,305 | $41,313,000 | 6.98% |
| TSFG, LLC | 91,132 | $7,971,000 | 6.10% |
| Veritas Asset Management LLP | 6,386,849 | $558,658,000 | 5.44% |
| Palmer Knight Co | 64,636 | $5,654,000 | 4.80% |
| Triodos Investment Management BV | 193,700 | $16,943,000 | 4.30% |
| Progressive Investment Management Corp | 82,216 | $7,191,000 | 3.85% |
| Alphinity Investment Management Pty Ltd | 362,173 | $31,679,000 | 3.65% |
| HealthCor Management, L.P. | 1,032,820 | $90,341,000 | 3.42% |
| Sivik Global Healthcare LLC | 75,000 | $6,560,000 | 3.31% |